AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) shares traded down 2.5% during trading on Thursday . The company traded as low as $4.4750 and last traded at $4.71. 64,589 shares were traded during trading, an increase of 312% from the average session volume of 15,685 shares. The stock had previously closed at $4.83.
AlloVir Stock Down 2.5%
The company has a market cap of $23.75 million, a PE ratio of -0.23 and a beta of 0.63. The stock has a 50-day moving average of $4.75 and a 200-day moving average of $7.08.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Featured Stories
- Five stocks we like better than AlloVir
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
